BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27780311)

  • 1. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.
    Zhao H; Hei N; Wu Y; Chan W; Lei X; Cameron C; Chang S; Chavez-MacGregor M; Giordano SH
    Cancer; 2017 May; 123(6):940-947. PubMed ID: 27780311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen Initiation After Ductal Carcinoma In Situ.
    Nichols HB; Bowles EJ; Islam J; Madziwa L; Stürmer T; Tran DT; Buist DS
    Oncologist; 2016 Feb; 21(2):134-40. PubMed ID: 26768485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base.
    Flanagan MR; Rendi MH; Gadi VK; Calhoun KE; Gow KW; Javid SH
    Ann Surg Oncol; 2015 Oct; 22(10):3264-72. PubMed ID: 26202556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen in ductal carcinoma in situ.
    Daly MB
    Semin Oncol; 2006 Dec; 33(6):647-9. PubMed ID: 17145343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adherence to adjuvant hormonal therapy in patients with breast cancer].
    Camejo-Martínez N; Castillo-Leska C; Artagaveytia-Cóppola NA; Hernández-Ibero AL; Amarillo-Hernández DL; Apud-Yumati PS; Melo-Ramundo F; Delgado-Pebe LB
    Rev Med Inst Mex Seguro Soc; 2019 Dec; 57(6):357-363. PubMed ID: 33001611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study.
    Nguyen TT; Hoskin TL; Day CN; Habermann EB; Goetz MP; Boughey JC
    Ann Surg Oncol; 2017 Oct; 24(10):2989-2998. PubMed ID: 28766214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
    Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
    Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma
    Trivedi MS; Coe AM; Vanegas A; Kukafka R; Crew KD
    Cancer Prev Res (Phila); 2017 Aug; 10(8):434-441. PubMed ID: 28611039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.
    Farias AJ; Du XL
    Med Oncol; 2016 Feb; 33(2):19. PubMed ID: 26786154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tamoxifen Acceptance and Adherence among Patients with Ductal Carcinoma In Situ (DCIS) Treated in a Multidisciplinary Setting.
    Karavites LC; Kane AK; Zaveri S; Xu Y; Helenowski I; Hansen N; Bethke KP; Rasmussen-Torvik LJ; Khan SA
    Cancer Prev Res (Phila); 2017 Jul; 10(7):389-397. PubMed ID: 28559459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma.
    Nakhlis F; Lazarus L; Hou N; Acharya S; Khan SA; Staradub VL; Rademaker AW; Morrow M
    J Am Coll Surg; 2005 Nov; 201(5):688-94. PubMed ID: 16256910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
    Farias AJ; Du XL
    J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race.
    Madubata CC; Liu Y; Goodman MS; Yun S; Yu J; Lian M; Colditz GA
    Breast Cancer Res Treat; 2016 Dec; 160(3):563-572. PubMed ID: 27771840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
    Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
    Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.
    Yen TW; Kuerer HM; Ottesen RA; Rouse L; Niland JC; Edge SB; Theriault RL; Weeks JC
    J Clin Oncol; 2007 Aug; 25(22):3251-8. PubMed ID: 17577019
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.